Home › Companies › DAY ONE BIOPHARMACEUTICALS INC. › 2024-2025
Compiled from SEC Form N-PX filings and DAY ONE BIOPHARMACEUTICALS INC.’s Form 8-K, filed June 3, 2025 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 2, 2025: 4 items on DAY ONE BIOPHARMACEUTICALS INC.’s Form 8-K, filed June 3, 2025: 4 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore DAY ONE BIOPHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are DAY ONE BIOPHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Natalie Holles | 81,975,302 | -- | -- | 1,357,027 | 6,470,934 | 98% | Not verified | — |
| Elect Director: Garry Nicholson, M.B.A. | 65,553,238 | -- | -- | 17,779,091 | 6,470,934 | 79% | Not verified | — |
| 2. The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. | 89,705,033 | 74,951 | 23,279 | -- | -- | 99.9% | Not verified | — |
| 3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. | 82,385,592 | 879,957 | 66,780 | -- | 6,470,934 | 99% | Not verified | — |
Source: DAY ONE BIOPHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 3, 2025 — read the filing on EDGAR.
Each item below shows how the 167 asset managers that disclosed a DAY ONE BIOPHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Garry Nicholson
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Garry Nicholson, M.B.A.”): 65,553,238 for, 17,779,091 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 22,866,484 for, 1,239,733 withheld, 104,089 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 379,585 | Withhold |
| State Street | 335 | 0 | 0 | 154,122 | Withhold |
| Equitable | 85,995 | 0 | 0 | 62,790 | Mixed |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 110,000 | Withhold |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 0 | 0 | 0 | 77,906 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 76,829 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 67,343 | Withhold |
| SEI | 0 | 0 | 0 | 66,100 | Withhold |
| Exchange Place Advisors Trust | 0 | 0 | 49,857 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 40,345 | Withhold |
| ProShares | 0 | 0 | 0 | 38,925 | Withhold |
| Northern Trust | 0 | 0 | 0 | 32,325 | Withhold |
| Global X | 0 | 0 | 0 | 32,210 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 28,227 | Withhold |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Natalie Holles
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Natalie Holles”): 81,975,302 for, 1,357,027 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 23,717,591 for, 473,269 withheld, 19,446 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 379,585 | Withhold |
| State Street | 154,457 | 0 | 0 | 0 | For |
| Equitable | 85,995 | 0 | 0 | 62,790 | Mixed |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 110,000 | 0 | 0 | 0 | For |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 77,906 | 0 | 0 | 0 | For |
| Lincoln Financial | 73,329 | 0 | 0 | 3,500 | For |
| ALPS ETF Trust | 67,343 | 0 | 0 | 0 | For |
| SEI | 66,100 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,857 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| Brighthouse | 20,948 | 0 | 0 | 19,397 | Mixed |
| ProShares | 38,925 | 0 | 0 | 0 | For |
| Northern Trust | 32,325 | 0 | 0 | 0 | For |
| Global X | 32,210 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,227 | 0 | 0 | 0 | For |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
Combines 7 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.”): 82,385,592 for, 879,957 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 379,585 | 0 | 0 | 0 | For |
| State Street | 154,457 | 0 | 0 | 0 | For |
| Equitable | 148,785 | 0 | 0 | 0 | For |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 110,000 | 0 | 0 | 0 | For |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 77,906 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,829 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 67,343 | 0 | 0 | 0 | For |
| SEI | 66,100 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,857 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| Brighthouse | 20,948 | 0 | 19,397 | 0 | Mixed |
| ProShares | 38,925 | 0 | 0 | 0 | For |
| Northern Trust | 32,325 | 0 | 0 | 0 | For |
| Global X | 32,210 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,227 | 0 | 0 | 0 | For |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
Fund voting reports, all 53 managers: 24,189,860 for, 1,049 against, 19,397 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 12,119,185 | 0 | 0 | 0 | For |
| Atlas Venture Life Science Advisors, LLC | 6,430,257 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 4,913,327 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 3,935,683 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 3,348,466 | 0 | 0 | 0 | For |
| Estuary Capital Management LP | 3,318,406 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,753,557 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 2,113,323 | 0 | 0 | 0 | For |
| BlackRock | 1,945,413 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 1,865,684 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,736,748 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,529,920 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,128,505 | 0 | 0 | 0 | For |
| State Street | 1,003,240 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 862,068 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 761,363 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 662,197 | 0 | 0 | 0 | For |
| Charles Schwab | 527,998 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 430,814 | 0 | 0 | 0 | For |
| Northern Trust | 377,567 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 364,238 | 0 | 0 | 0 | For |
| UniSuper Management Pty Ltd | 350,000 | 0 | 0 | 0 | For |
| Citadel | 294,936 | 0 | 0 | 0 | For |
| AQR | 294,780 | 0 | 0 | 0 | For |
| NOMURA ASSET MANAGEMENT CO LTD | 249,625 | 0 | 0 | 0 | For |
Institutional-manager reports, all 133 managers: 55,918,366 for, 207,754 against, 106 not voted. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“2. The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”): 89,705,033 for, 74,951 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 24,190,909 for, 19,397 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 379,585 | 0 | 0 | 0 | For |
| State Street | 154,457 | 0 | 0 | 0 | For |
| Equitable | 148,785 | 0 | 0 | 0 | For |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 110,000 | 0 | 0 | 0 | For |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 77,906 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,829 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 67,343 | 0 | 0 | 0 | For |
| SEI | 66,100 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,857 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| Brighthouse | 20,948 | 0 | 19,397 | 0 | Mixed |
| ProShares | 38,925 | 0 | 0 | 0 | For |
| Northern Trust | 32,325 | 0 | 0 | 0 | For |
| Global X | 32,210 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,227 | 0 | 0 | 0 | For |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
Not shown here: this season’s fund filings also report 1 item from the meeting of May 23, 2024, which belongs to the 2023-2024 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 87,389,859 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 12.28% |
| 2 | Vanguard | 6.67% |
| 3 | FRANKLIN STRATEGIC SERIES | 2.67% |
| 4 | BlackRock | 2.48% |
| 5 | T. Rowe Price | 0.87% |
| 6 | Charles Schwab | 0.60% |
| 7 | Dimensional | 0.43% |
| 8 | State Street | 0.18% |
| 9 | Equitable | 0.17% |
| 10 | TIAA | 0.16% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 13.87% |
| 2 | Atlas Venture Life Science Advisors, LLC | 7.36% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 5.62% |
| 4 | FRANKLIN ADVISERS INC | 4.50% |
| 5 | PICTET ASSET MANAGEMENT SA | 3.83% |
| 6 | Estuary Capital Management LP | 3.80% |
| 7 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3.15% |
| 8 | BRAIDWELL LP | 2.42% |
| 9 | BlackRock | 2.23% |
| 10 | Alyeska Investment Group, L.P. | 2.13% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| AI Day 1 LLC | 15.74% | DEF14A |
| FMR (Fidelity) | 15.68% | 13F |
| Fidelity | 14.75% | DEF14A |
| BlackRock | 7.73% | 13F |
| Entities affiliated with Atlas Venture | 7.36% | DEF14A |
| Vanguard Group | 6.80% | 13F |
| RA Capital Management, L.P. | 6.59% | DEF14A |
| Glazer Capital, LLC | 6.43% | 13G |
| Franklin Templeton | 4.60% | 13F |
| Jeremy Bender, Ph.D., M.B.A. | 4.35% | DEF14A |
Percentages above are of 87,389,859 shares outstanding, as reported by DAY ONE BIOPHARMACEUTICALS INC. on its Form 10-Q dated May 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from DAY ONE BIOPHARMACEUTICALS INC.’s 10-Q dated May 1, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At DAY ONE BIOPHARMACEUTICALS INC.'s shareholder meeting held June 2, 2025, in the 2024-2025 proxy season, 167 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 903 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: DAY ONE BIOPHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2025.
DAY ONE BIOPHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).
Download data (CSV): ballot items · votes by manager · column guide.